Acute chest pain (ACP) is a common symptom that often presents a diagnostic challenge in clinical practice. The complexity lies in the wide differential diagnosis, ranging from benign conditions to life-threatening diseases such as acute myocardial infarction. This article aims to provide a comprehensive approach to evaluating ACP.
A thorough patient history is crucial in the evaluation of ACP. It provides valuable information about the onset, duration, character, and radiation of pain. Moreover, associated symptoms, risk factors for coronary artery disease, and previous medical history can guide the clinician towards a probable diagnosis.
Physical examination aids in narrowing down the differential diagnosis. Vital signs, cardiac and lung auscultation, palpation of the chest wall, and examination of the abdomen can provide clues about the cause of ACP. Additionally, signs of peripheral vascular disease or aortic dissection should be meticulously searched for.
Electrocardiogram (ECG) is the first-line diagnostic test in ACP. Changes in ECG can indicate myocardial ischemia or other cardiac conditions. Blood tests, including cardiac biomarkers, complete blood count, and D-dimer, can support the diagnosis. Further imaging studies such as chest X-ray, computed tomography, or echocardiography may be required based on clinical suspicion.
Risk stratification is essential to guide management. Several validated tools, such as the HEART score, can help estimate the risk of major adverse cardiac events. Patients at high risk require immediate intervention, while those at low risk may undergo further outpatient evaluation.
ACP evaluation requires a systematic approach that includes a detailed patient history, physical examination, appropriate diagnostic tests, and risk stratification. By adopting such a comprehensive approach, clinicians can ensure accurate diagnosis and timely management, thereby enhancing patient outcomes in ACP.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation